# **INVESTMENT OBJECTIVE**

Invests in SPI companies in which a significant part of the capital / voting rights is still owned by the founder, his descendants, a family or an entrepreneur. They are chosen according to a fundamental investment process which selects those with the best risk-opportunity profile.

# **PORTFOLIO REVIEW**


After several months of small- and mid-cap outperformance vs. large-cap peers in the Swiss market, the trend reversed in August. The SMI rose 3%, driven notably by strong gains from Nestlé (+6%), Novartis (+7%), UBS (+6%) and Zurich (+5%), while the SPI Extra was flat. A change in investor behaviour was also to be noted, shifting away from cyclical sectors such as industry, as well as growth stocks, towards more defensive sectors and companies with a greater « value » profile. The first half earnings season confirmed this rotation. A number of companies took a large hit, either because their results fell short of expectations or because their guidance for the latter part of the year proved more cautious. Conversely, some companies that had released excellent results in July and seen their share prices post sharp gains suffered significant profit-taking. In summary, August was a month of clear sector and style rotation within the Swiss market.

The Bruellan Swiss Family Enterprises fund closed the month down 2.1%.

The main performance detractors were Belimo, which, after gaining more than 60% between January and July, thanks to strong growth in its data centre business, underwent profit-taking. Skan was severely punished (-18%) after releasing disappointing results for its pharmaceutical industry isolator business. Finally, Bachem suffered a setback (-8%) after an excellent month of July. Lack of exposure to Nestlé and Novartis also cost the fund more than one point of relative performance.

A few stocks nonetheless upheld performance. Kardex (+7%) continues to benefit from a dynamic order book, Medartis (+6%) upped its full year growth outlook slightly, and VZ Holding (+6%) reported solid growth in assets under management. Also noteworthy was the recovery of Sonova, which, despite very good results released last May, pointing to significantly higher growth than its competitors, had been largely shunned by investors. The fact that the group indicated that it will certainly be exempt from customs duties, due to the Nairobi Protocol, was undoubtedly a factor in this rebound.

# **NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF**



	Fund	SPI Index	+/-
1 Month	-2.1%	2.3%	-4.4%
3 Months	0.5%	0.3%	0.2%
YTD	10.4%	9.3%	1.2%
Since inception	27.6%	39.4%	-11.8%

Source: All data and graphs throughout the document from Bruellan.  $\label{eq:control}$ 

Past performance may not be a reliable guide to future performance. All forms of investment involve risk.

The benchmark index is the SPI Index.

Please refer to the end of the document mentioned for performance comparison purposes.

# **RISK & REWARD**



Not all the costs are presented, further information can be found in the prospectus or equivalent.


Retail: 124.89 Instit.: 127.64 Early Bird: 129.51

# STATISTICS

NAV

	Fund	SPI Index
Leading PE	24.5	17.8
EV/EBITDA	15.7	11.9
P/Book	4.8	2.0
Dividend Yield	2.0%	2.7%
ROE	16.9%	8.2%
Debt/Equity	29.5%	54.4%
Interest Coverage	13.7	8.3
Beta	1.0	1.0
Volatility	16.1%	12.5%

# **ALLOCATION BY MARKET CAP**




# PROTEA BAM SWISS FAMILY ENTERPRISES





# **ALLOCATION BY SECTOR**



# **FUND COMPLEMENTARY DETAILS**

Administrator Representative in Switzerland Investment Manager Paying agent in Switzerland Auditor Custodian

Fund Partner Solutions SA FundPartner Solutions (Suisse) SA Bruellan SA Banque Pictet & Cie SA

Deloitte Audit SARL Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg

# **TOP 10 HOLDINGS**

	Sector	Weight
BELIMO HOLDING AG-REG	Industrials	6.8%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	5.9%
KARDEX HOLDING AG-REG	Industrials	5.7%
SWISSQUOTE GROUP HOLDING-REG	Financials	5.5%
MEDACTA GROUP SA	Health Care	5.3%
VZ HOLDING AG	Financials	5.1%
STRAUMANN HOLDING AG-REG	Health Care	4.6%
BACHEM HOLDING AG	Health Care	4.5%
EMMI AG-REG	Consumer Staples	4.2%
SONOVA HOLDING AG-REG	Health Care	4.1%
Total		51.8%
Total number of Holdings		27

Total number of Holdings

CONTACT

BRUELLAN SA Rue Pécolat 1 CH-1201 Genève Tél: +41 22 817 18 55

bam@bruellan.ch

Disclaimer. Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFin, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is

a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-a nual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link:

https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus. Information on sustainability-related aspects provided in relation to the promoted fund could be found on the following link: https://assetservices.group.pictet/asset-services/esg-disclosures?isin=LU1118008553. Incorporation of extra-financial risks into the investment decision process may result in underweighting of profitable investments from the sub-fund's investment universe and may also lead the management of the sub-fund to underweight investments that will continue to perform. The Fund has been classified as a financial product subject to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (the "SFDR"). The Fund promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices. Performance disclosures: the published performance represents past data. Past performance may not be a reliable guide to future performance. There is no guarantee that the same yields will be obtained in the future. The value and income of any of your investment may fluctuate with market conditions and may lose some or all its value. The fund may be affected by changes in currency exchange rates, which can have an adverse effect on the value or income of the fund. Future performance is also subject to taxation which depends on the personal situation of each investor and which may change in the future. All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed.